Loading...
Loading...
Moderna, Inc. MRNA shares are trading higher after analysts at multiple firms raised their price targets on the stock. The company has attracted investor interest recently, as it is working on a coronavirus (COVID-19) vaccine.
Morgan Stanley maintained an Overweight rating and raised its price target from $30 to $37.
Oppenheimer maintained an Outperform rating and raised its price target from $31 to $43.
Moderna shares were trading up 10.65%, hitting a 52-week high of $38.35 on Wednesday. The stock has a 52-week low of 11.54.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in